Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics


Eloxx Pharmaceuticals, Inc. (ELOX)

Today's Latest Price: $2.79 USD

0.16 (6.08%)

Updated Sep 25 4:00pm

Add ELOX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ELOX Daily Price Range
ELOX 52-Week Price Range

ELOX Stock Price Chart Technical Analysis Charts


ELOX Price/Volume Stats

Current price $2.79 52-week high $8.16
Prev. close $2.63 52-week low $1.44
Day low $2.51 Volume 31,159
Day high $2.81 Avg. volume 132,319
50-day MA $3.03 Dividend yield N/A
200-day MA $3.56 Market Cap 111.99M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio


Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.


ELOX Latest News Stream


Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream


Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant

WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities. “We are very pleased to welcome to Eloxx someone of Dr. Kerem’s caliber and recognized expertise in cystic fibrosis as we advance our Pha...

Yahoo | September 14, 2020

Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October

WALTHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts will be presented at the North American Cystic Fibrosis Conference (NACFC) to be held virtually starting on October 7, 2020. The two abstracts will be showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology. These virtual posters will be available to registered attendees on the NACFC online conference platform starting on October 7, 2020. “We are pleased to be presenting addition...

Yahoo | August 26, 2020

Eloxx Pharma restarts mid-stage cystic fibrosis study in U.S.

Eloxx Pharmaceuticals (ELOX) jumps 9% premarket in reaction to the resumption of enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis in U.S. which was temporarily paused in response to the COVID-19 pandemic.On June 17, enrollment resumed in Phase 2 cystic fibrosis trial in Europe and Israel too. “Our highest priority is...

Seeking Alpha | August 12, 2020

Eloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call Transcript

Eloxx Pharmaceuticals, Inc. (ELOX) Q2 2020 Earnings Conference Call August 06, 2020 2:00 PM ET Company Participants Barbara Ryan – Investor Relations Greg Williams – Chief Executive Officer Neil Belloff – Chief Operating Officer and General Counsel Matthew Goddeeris – Vice President-Research Stephen MacDonald – Vice President-Finance and Accounting Conference...

SA Transcripts on Seeking Alpha | August 8, 2020

Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemicU.S. FDA has granted orphan drug designation for ELX-02 for the treatment of cystic fibrosisCompleting enrollment in our Phase 2 cystic fibrosis clinical trials and reporting top line data remain our highest prioritiesPreclinical studies continuing to advance in autosomal dominant polycystic kidney disease (ADPKD) and inherited retinal disorders Cash and cash equivalents of $37.1 million as of June 30, 2020 provides cash runway through the end of 2021Company to host webcast and conference call today, Thursday, August 6, 2020, at 2:00 pm ETWALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- August 6, 2020 – Eloxx Pha...

Yahoo | August 6, 2020

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo -15.45%
3-mo -6.38%
6-mo 30.99%
1-year -38.00%
3-year -51.88%
5-year -74.64%
YTD -62.09%
2019 -38.72%
2018 50.13%
2017 185.31%
2016 -64.86%
2015 -51.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6935 seconds.